Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of kidney failure worldwide. ADPKD is characterized by clusters of fluid-filled cysts in both kidneys, associated with a gradual decline in kidney function.
Explore the latest ISN Global Trials Focus selections featuring a “Trial of the month” on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan
ISN-ACT Global Trials Focus editorial team member Michele Provenzano summarizes the design and outcomes of the latest "Trial of the month" featured in ISN-ACT Global Trials Focus. Trial of the month: DAPA-tolvaptan: First trial of SGLT2 inhibition in ADPKD with background tolvaptan therapy Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan Uchiyama...